{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:25:18Z","timestamp":1792160718469,"version":"4.4.0"},"reference-count":107,"publisher":"American Medical Association (AMA)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec id=\"ab-jrv260005-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Endometrial cancer accounts for 95% of uterine cancers. Uterine cancers are the fourth most common cancer in women in the US, with an estimated 68\u202f270 new cases and 14\u202f450 cancer deaths projected to occur in 2026. The US mortality rate from uterine cancer rose by 1.6% annually from 2014 to 2023, increasing from 4.8 deaths per 100\u202f000 persons to 5.6 deaths per 100\u202f000 persons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv260005-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Endometrial cancer develops most commonly due to the effect of estrogen on the uterine lining. Circulating estrogen is produced by adipose cells; rising obesity rates are correlated with an increase in US endometrial cancer incidence from 2013 to 2022 (26.4 per 100\u202f000 in 2013 and 28.8 per 100\u202f000 in 2022). Although 80% of endometrial cancers arise in postmenopausal women, the incidence increased from 2000 to 2019 by 3.0% annually in women aged 20 to 29 years and 3.3% annually in women aged 30 to 39 years. The age-adjusted incidence of endometrial cancer is similar among Black and White women, but mortality was 18.4 per 100\u202f000 among Black women and 8.1 per 100\u202f000 among White women from 2019 to 2023. Many patients (75%-90%) with endometrial cancer present with vaginal bleeding, which should be evaluated with office endometrial biopsy or surgical dilation and curettage for pathologic diagnosis. Initial endometrial cancer management is surgery, including hysterectomy, bilateral salpingo-oophorectomy, and lymph node assessment. Ovarian retention can be considered in select younger patients. Surgical pathology defines histology and molecular subtype, which guide staging and adjuvant therapy. Early-stage, low-risk disease is managed with observation after surgery. Patients with early-stage, high-intermediate risk disease typically undergo adjuvant radiation therapy and patients with aggressive histologic subtypes or advanced-stage disease are treated with adjuvant chemotherapy. First-line chemotherapy for advanced-stage endometrial cancer is carboplatin and paclitaxel plus consideration of anti\u2013programmed cell death protein 1 immunotherapy. Radiation therapy is used for localized recurrences in the pelvis; distant or multifocal recurrences are treated with systemic therapy, including chemotherapy, without or with immunotherapy, or hormonal therapy such as progestins or antiestrogens. Five-year survival is greater than 86% for stage I endometrial cancer, greater than 75% for stage II, greater than 41% for stage III, and greater than 18% for stage IV disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv260005-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Endometrial cancer accounts for 95% of uterine cancers, which are the fourth most common cancer in women in the US. Surgery is first-line treatment. Adjuvant radiation is recommended for early-stage, high-intermediate risk endometrial cancer. Adjuvant chemotherapy with carboplatin and paclitaxel is recommended for early-stage disease with aggressive histologic subtypes and advanced-stage disease, which is also treated with immunotherapy in some cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2026.2248","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:30:37Z","timestamp":1776094237000},"page":"1616","source":"Crossref","is-referenced-by-count":18,"title":["Endometrial Cancer"],"prefix":"10.1001","volume":"335","author":[{"given":"Katherine L.","family":"Mager","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"McLean","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York"},{"name":"Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"jrv260005r1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026.","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"jrv260005r2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajog.2024.06.026","article-title":"Uterine cancer incidence trends and 5-year relative survival by race\/ethnicity and histology among women under 50 years.","volume":"231","author":"Wijayabahu","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"22","key":"jrv260005r3","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1200\/JCO.19.00151","article-title":"Hysterectomy-corrected uterine corpus cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of nonendometrioid cancers.","volume":"37","author":"Clarke","year":"2019","journal-title":"J Clin Oncol"},{"issue":"32","key":"jrv260005r4","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.1200\/JCO.2009.22.3248","article-title":"Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2.","volume":"27","author":"Walker","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"jrv260005r5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S1470-2045(17)30068-2","article-title":"A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study.","volume":"18","author":"Rossi","year":"2017","journal-title":"Lancet Oncol"},{"key":"jrv260005r6","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8884364","article-title":"Endometrial tumor classification by histomorphology and biomarkers in the Nurses\u2019 Health Study.","volume":"2021","author":"Watkins","year":"2021","journal-title":"J Cancer Epidemiol"},{"issue":"2","key":"jrv260005r7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers.","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"issue":"8","key":"jrv260005r8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.6004\/jnccn.2025.0038","article-title":"NCCN Guidelines insights: uterine neoplasms, version 3.2025.","volume":"23","author":"Abu-Rustum","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"jrv260005r9","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1200\/JCO.2009.24.1315","article-title":"Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.","volume":"28","author":"Lacey","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"jrv260005r10","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/cncr.21650","article-title":"Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.","volume":"106","author":"Trimble","year":"2006","journal-title":"Cancer"},{"issue":"35","key":"jrv260005r11","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1200\/JCO.2016.69.4638","article-title":"Addressing the role of obesity in endometrial cancer risk, prevention, and treatment.","volume":"34","author":"Onstad","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"jrv260005r12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012513.pub3","article-title":"Interventions for weight reduction in obesity to improve survival in women with endometrial cancer.","volume":"3","author":"Agnew","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"jrv260005r13","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/ijc.31961","article-title":"Risk factors for endometrial cancer: an umbrella review of the literature.","volume":"145","author":"Raglan","year":"2019","journal-title":"Int J Cancer"},{"issue":"7630","key":"jrv260005r14","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1136\/bmj.39367.495995.AE","article-title":"Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study.","volume":"335","author":"Reeves","year":"2007","journal-title":"BMJ"},{"issue":"5","key":"jrv260005r15","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s11695-018-3151-x","article-title":"Does bariatric surgery affect the incidence of endometrial cancer development? a systematic review.","volume":"28","author":"Winder","year":"2018","journal-title":"Obes Surg"},{"issue":"6","key":"jrv260005r16","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1097\/01.AOG.0000450757.18294.cf","article-title":"Committee Opinion No. 601: tamoxifen and uterine cancer.","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"1","key":"jrv260005r17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12905-022-02028-x","article-title":"The association between endometriosis and risk of endometrial cancer and breast cancer: a meta-analysis.","volume":"22","author":"Ye","year":"2022","journal-title":"BMC Womens Health"},{"issue":"9","key":"jrv260005r18","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(15)00212-0","article-title":"Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies.","volume":"16","author":"Collaborative Group on Epidemiological Studies on Endometrial Cancer","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"jrv260005r19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000402.pub4","article-title":"Hormone therapy in postmenopausal women and risk of endometrial hyperplasia.","volume":"2012","author":"Furness","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"jrv260005r20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.maturitas.2016.05.013","article-title":"Hormone replacement therapy and the risk of endometrial cancer: a systematic review.","volume":"91","author":"Sj\u00f6gren","year":"2016","journal-title":"Maturitas"},{"issue":"5","key":"jrv260005r21","doi-asserted-by":"publisher","first-page":"E410","DOI":"10.1002\/ijc.29229","article-title":"Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium.","volume":"136","author":"Felix","year":"2015","journal-title":"Int J Cancer"},{"issue":"1","key":"jrv260005r22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ygyno.2014.07.095","article-title":"Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? a systematic review and meta-analysis of cohort studies.","volume":"135","author":"Liao","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"7","key":"jrv260005r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes.","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"10","key":"jrv260005r24","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 receptor agonists and cancer risk in adults with obesity.","volume":"11","author":"Dai","year":"2025","journal-title":"JAMA Oncol"},{"issue":"2","key":"jrv260005r25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.7326\/ANNALS-25-02237","article-title":"Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: a systematic review and meta-analysis.","volume":"179","author":"Ko","year":"2025","journal-title":"Ann Intern Med"},{"issue":"10","key":"jrv260005r26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.6004\/jnccn.2024.0061","article-title":"Genetic\/familial high-risk assessment: colorectal, endometrial, and gastric, version 3.2024, NCCN Clinical Practice Guidelines in oncology.","volume":"22","author":"Hodan","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"jrv260005r27","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","article-title":"NCCN guidelines insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024.","volume":"21","author":"Daly","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"jrv260005r28","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/jnci\/djab036","article-title":"Endometrial cancer risk in women with germline BRCA1 or BRCA2 mutations: multicenter cohort study.","volume":"113","author":"de Jonge","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"jrv260005r29","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/AOG.0000000000002631","article-title":"ACOG Committee opinion No. 734: the role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding.","volume":"131","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"1","key":"jrv260005r30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/24731242251365480","article-title":"Beyond bleeding: an analysis of presenting symptoms among Black patients with endometrial cancer.","volume":"9","author":"Gross","year":"2025","journal-title":"Health Equity"},{"issue":"3","key":"jrv260005r31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ygyno.2009.05.019","article-title":"Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods.","volume":"114","author":"Zhao","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"5","key":"jrv260005r32","first-page":"73","article-title":"Endometrial cancer prevalence in women with an incidental finding of thickened endometrium.","volume":"118","author":"Stokes","year":"2025","journal-title":"Ir Med J"},{"key":"jrv260005r33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejogrb.2018.02.017","article-title":"The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications.","volume":"223","author":"Parsons","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"8","key":"jrv260005r34","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1001\/jamaoncol.2024.1891","article-title":"Endometrial thickness as diagnostic triage for endometrial cancer among Black individuals.","volume":"10","author":"Doll","year":"2024","journal-title":"JAMA Oncol"},{"issue":"8","key":"jrv260005r35","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1001\/jamaoncol.2021.1700","article-title":"Estimated performance of transvaginal ultrasonography for evaluation of postmenopausal bleeding in a simulated cohort of black and white women in the US.","volume":"7","author":"Doll","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"jrv260005r36","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ygyno.2005.09.042","article-title":"Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers.","volume":"101","author":"Wang","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"9","key":"jrv260005r37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/jcu.22631","article-title":"Risk of endometrial cancer and endometrial hyperplasia with atypia in asymptomatic postmenopausal women with endometrial thickness =11 mm: a systematic review and meta-analysis.","volume":"46","author":"Alc\u00e1zar","year":"2018","journal-title":"J Clin Ultrasound"},{"issue":"12","key":"jrv260005r38","doi-asserted-by":"publisher","first-page":"7716","DOI":"10.21037\/tcr.2020.04.20","article-title":"Current role of Pipelle endometrial sampling in early diagnosis of endometrial cancer.","volume":"9","author":"Terzic","year":"2020","journal-title":"Transl Cancer Res"},{"issue":"6","key":"jrv260005r39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-072124","article-title":"Diagnostic accuracy of endometrial sampling tests for detecting endometrial cancer: a systematic review and meta-analysis.","volume":"13","author":"Sakna","year":"2023","journal-title":"BMJ Open"},{"issue":"4","key":"jrv260005r40","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1097\/01.AOG.0000462977.61229.de","article-title":"Practice Bulletin No. 149: endometrial cancer.","volume":"125","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"7","key":"jrv260005r41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1200\/JCO.2011.38.8645","article-title":"Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 study.","volume":"30","author":"Walker","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"jrv260005r42","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1001\/jama.2017.2068","article-title":"Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial.","volume":"317","author":"Janda","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"jrv260005r43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/AOG.0000000000001181","article-title":"Utilization and outcomes of ovarian conservation in premenopausal women with endometrial cancer.","volume":"127","author":"Wright","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"5","key":"jrv260005r44","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/IGC.0b013e3182954da8","article-title":"Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging.","volume":"23","author":"Kim","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"jrv260005r45","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ygyno.2012.02.021","article-title":"The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes.","volume":"125","author":"Barlin","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"2","key":"jrv260005r46","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ygyno.2011.04.030","article-title":"Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes.","volume":"122","author":"Khoury-Collado","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"2","key":"jrv260005r47","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023.","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"jrv260005r48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium.","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"issue":"7447","key":"jrv260005r49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma.","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"5","key":"jrv260005r50","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series.","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"jrv260005r51","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ygyno.2022.10.024","article-title":"Molecular testing for endometrial cancer: an SGO clinical practice statement.","volume":"168","author":"Walsh","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"7","key":"jrv260005r52","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1158\/2159-8290.CD-24-1678","article-title":"Trends in cancer incidence and mortality rates in early-onset and older-onset age groups in the United States, 2010-2019.","volume":"15","author":"Shiels","year":"2025","journal-title":"Cancer Discov"},{"issue":"2","key":"jrv260005r53","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ygyno.2012.11.025","article-title":"MRI, PET\/CT and ultrasound in the preoperative staging of endometrial cancer: a multicenter prospective comparative study.","volume":"128","author":"Antonsen","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"4","key":"jrv260005r54","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5468\/ogs.19169","article-title":"Fertility-sparing treatment in early endometrial cancer: current state and future strategies.","volume":"63","author":"Obermair","year":"2020","journal-title":"Obstet Gynecol Sci"},{"issue":"12","key":"jrv260005r55","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1200\/JCO-24-02782","article-title":"Fertility preservation in people with cancer: ASCO guideline update.","volume":"43","author":"Su","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"jrv260005r56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajog.2020.08.032","article-title":"Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.","volume":"224","author":"Westin","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"jrv260005r57","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ygyno.2011.11.043","article-title":"Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.","volume":"125","author":"Baker","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"7","key":"jrv260005r58","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013111.pub2","article-title":"Fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.","volume":"7","author":"Fernandez-Montoli","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"jrv260005r59","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ygyno.2012.01.003","article-title":"Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.","volume":"125","author":"Gunderson","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"5","key":"jrv260005r60","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.brachy.2015.06.002","article-title":"Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer.","volume":"14","author":"Schwarz","year":"2015","journal-title":"Brachytherapy"},{"key":"jrv260005r61","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejca.2016.07.005","article-title":"Systemic review: radiation therapy alone in medical non-operable endometrial carcinoma.","volume":"65","author":"van der Steen-Banasik","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"jrv260005r62","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ygyno.2021.09.006","article-title":"Patterns of care and outcomes of radiotherapy or hormone therapy in patients with medically inoperable endometrial adenocarcinoma.","volume":"163","author":"Reshko","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"3","key":"jrv260005r63","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"9213","key":"jrv260005r64","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial.","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"jrv260005r65","doi-asserted-by":"publisher","first-page":"e631","DOI":"10.1016\/j.ijrobp.2011.04.013","article-title":"Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma.","volume":"81","author":"Creutzberg","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9717","key":"jrv260005r66","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"jrv260005r67","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.ygyno.2020.12.021","article-title":"Endometrial cancer: a society of gynecologic oncology evidence-based review and recommendations.","volume":"160","author":"Hamilton","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"2","key":"jrv260005r68","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/IGC.0b013e3182094ded","article-title":"The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study.","volume":"21","author":"Vandenput","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"jrv260005r69","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ygyno.2005.06.012","article-title":"Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.","volume":"98","author":"Kelly","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"29","key":"jrv260005r70","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy.","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"jrv260005r71","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/IGC.0000000000000643","article-title":"Role of adjuvant therapy for stage IA serous and clear cell uterine cancer: is observation a valid strategy?","volume":"26","author":"Velker","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"24","key":"jrv260005r72","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer.","volume":"380","author":"Matei","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"jrv260005r73","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.24.01121","article-title":"Long-term follow-up and overall survival in NRG258, a randomized phase III trial of chemoradiation versus chemotherapy for locally advanced endometrial carcinoma.","volume":"43","author":"Matei","year":"2025","journal-title":"J Clin Oncol"},{"issue":"23","key":"jrv260005r74","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer.","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv260005r75","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat Med"},{"issue":"23","key":"jrv260005r76","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer.","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"jrv260005r77","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial.","volume":"35","author":"Powell","year":"2024","journal-title":"Ann Oncol"},{"issue":"20","key":"jrv260005r78","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu.","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv260005r79","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial.","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"jrv260005r80","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability: high advanced endometrial cancer: results from the KEYNOTE-158 study.","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv260005r81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003777","article-title":"Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) or proficient\/stable (MMRp\/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.","volume":"10","author":"Oaknin","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"16","key":"jrv260005r82","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1200\/JCO.22.02152","article-title":"Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309\/KEYNOTE-775.","volume":"41","author":"Makker","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"jrv260005r83","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ygyno.2021.12.031","article-title":"A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: a GOG Foundation study.","volume":"164","author":"Slomovitz","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"1","key":"jrv260005r84","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ygyno.2019.05.007","article-title":"Phase 2 study of anastrozole in recurrent estrogen (ER)\/progesterone (PR) positive endometrial cancer: the PARAGON trial: ANZGOG 0903.","volume":"154","author":"Mileshkin","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"jrv260005r85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study.","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"jrv260005r86","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15","key":"jrv260005r87","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis.","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"jrv260005r88","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma.","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"jrv260005r89","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1136\/ijgc-2020-001929","article-title":"PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.","volume":"30","author":"van den Heerik","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"jrv260005r90","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1470-2045(25)00612-6","article-title":"Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial.","volume":"27","author":"van den Heerik","year":"2026","journal-title":"Lancet Oncol"},{"issue":"1","key":"jrv260005r91","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/ijgc-2022-004039","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program.","volume":"33","author":"Consortium","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"jrv260005r92","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1158\/1535-7163.MCT-24-0763","article-title":"Advances in antibody-drug conjugates for endometrial cancer.","volume":"24","author":"Tu","year":"2025","journal-title":"Mol Cancer Ther"},{"issue":"suppl 16","key":"jrv260005r93","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1200\/JCO.2025.43.16_suppl.3039","article-title":"Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: first disclosure from dose expansion cohort B2 of the GTC1184-01 study.","volume":"43","author":"Winer","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"jrv260005r94","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ygyno.2018.05.024","article-title":"Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.","volume":"150","author":"Mayor","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"15","key":"jrv260005r95","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.3390\/ijms26157151","article-title":"Feasibility of manufacturing and antitumor activity of TIL for advanced endometrial cancers.","volume":"26","author":"Zhang","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"4","key":"jrv260005r96","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.3390\/cimb45040220","article-title":"The current status and future perspectives of chimeric antigen receptor-engineered T cell therapy for the management of patients with endometrial cancer.","volume":"45","author":"Choi","year":"2023","journal-title":"Curr Issues Mol Biol"},{"key":"jrv260005r98","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ygyno.2024.04.016","article-title":"Prognostic performance of the 2023 FIGO staging schema for endometrial cancer.","volume":"187","author":"Matsuo","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"6","key":"jrv260005r99","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/jnci\/djad027","article-title":"Racial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries.","volume":"115","author":"Xu","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"jrv260005r100","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.ajog.2020.02.041","article-title":"Black and Hispanic women are less likely than white women to receive guideline-concordant endometrial cancer treatment.","volume":"223","author":"Kaspers","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"jrv260005r101","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ygyno.2025.11.014","article-title":"Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: a Society of Gynecologic Oncology clinical practice statement.","volume":"204","author":"Salani","year":"2026","journal-title":"Gynecol Oncol"},{"issue":"2","key":"jrv260005r102","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ygyno.2017.11.007","article-title":"Life after endometrial cancer: a systematic review of patient-reported outcomes.","volume":"148","author":"Shisler","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"1","key":"jrv260005r103","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ygyno.2020.10.023","article-title":"GOG 244: the Lymphedema and Gynecologic Cancer (LeG) study: the impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function.","volume":"160","author":"Carter","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"2","key":"jrv260005r104","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ygyno.2011.07.035","article-title":"Survivors of endometrial cancer: who is at risk for sexual dysfunction?","volume":"123","author":"Onujiogu","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"2","key":"jrv260005r105","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ygyno.2015.11.010","article-title":"Maintaining sexual health throughout gynecologic cancer survivorship: a comprehensive review and clinical guide.","volume":"140","author":"Huffman","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"2","key":"jrv260005r106","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ajog.2019.08.043","article-title":"Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy.","volume":"222","author":"Crean-Tate","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"jrv260005r107","doi-asserted-by":"publisher","first-page":"208","DOI":"10.6004\/jnccn.2025.0028","article-title":"NCCN Guidelines insights: survivorship, version 2.2025.","volume":"23","author":"Sanft","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"jrv260005r97","unstructured":"Cancer stat facts: uterine cancer. National Cancer Institute. Accessed March 6, 2026. https:\/\/seer.cancer.gov\/statfacts\/html\/corp.html"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2847570\/jama_mager_2026_rv_260005_1777583525.33154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:00:51Z","timestamp":1778598051000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2847570"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":107,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.2248","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}